Novo Nordisk A/S (NYSE:NVO) Shares Bought by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,186 shares of the company’s stock after acquiring an additional 308 shares during the period. Marks Group Wealth Management Inc’s holdings in Novo Nordisk A/S were worth $1,650,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NVO. Daiwa Securities Group Inc. purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Capital Performance Advisors LLP purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at $42,000. Albion Financial Group UT increased its stake in Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares during the last quarter. Sound Income Strategies LLC lifted its position in Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after buying an additional 243 shares during the period. Finally, Hager Investment Management Services LLC purchased a new position in Novo Nordisk A/S during the fourth quarter worth about $46,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday. They issued an “equal weight” rating on the stock. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $81.78 on Thursday. The company has a quick ratio of 0.75, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $366.99 billion, a P/E ratio of 24.86, a PEG ratio of 0.96 and a beta of 0.45. The firm has a fifty day moving average of $90.45 and a 200-day moving average of $110.60. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts predict that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 21.88%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.